A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning

Trial Profile

A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors EIP Pharma
  • Most Recent Events

    • 18 Jul 2017 New positive results were published in an EIP Pharma media release.
    • 18 Jul 2017 According to an EIP Pharma media release, new positive data was presented at the Alzheimer's Association International Conference (AAIC) 2017.
    • 08 Dec 2016 Results published in a EIP Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top